|
gptkbp:instanceOf
|
gptkb:cancer
brain tumor
|
|
gptkbp:affects
|
Adults
Children
|
|
gptkbp:alternativeName
|
gptkb:High-grade_glioma
gptkb:HGG
|
|
gptkbp:clinicalTrialPhase
|
gptkb:Bevacizumab
Tumor treating fields
|
|
gptkbp:grades
|
Grade III
Grade IV
|
|
gptkbp:hasBiomarker
|
gptkb:IDH_mutation
MGMT promoter methylation
1p/19q co-deletion
|
|
gptkbp:hasEpidemiology
|
More common in males
Incidence increases with age
|
|
gptkbp:hasFirstLineTherapy
|
gptkb:Temozolomide
Radiotherapy
Maximal safe resection
|
|
gptkbp:hasImagingFinding
|
Contrast-enhancing mass on MRI
|
|
gptkbp:hasLocation
|
gptkb:Brain
gptkb:Central_nervous_system
|
|
gptkbp:hasMedianSurvival
|
12-18 months
|
|
gptkbp:hasRecurrence
|
gptkb:Common
|
|
gptkbp:histology
|
Necrosis
Microvascular proliferation
High mitotic activity
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Malignant glioma
|
|
gptkbp:ICD-10_code
|
C71
|
|
gptkbp:originatedIn
|
Glial cells
|
|
gptkbp:prognosis
|
Poor
Age
Molecular markers
Performance status
|
|
gptkbp:riskFactor
|
gptkb:Ionizing_radiation
Genetic predisposition
|
|
gptkbp:stageName
|
WHO grading
|
|
gptkbp:subspecies
|
gptkb:Anaplastic_astrocytoma
gptkb:Anaplastic_oligodendroglioma
gptkb:Glioblastoma
|
|
gptkbp:symptom
|
gptkb:Nausea
Headache
Vomiting
Seizures
Cognitive impairment
Weakness
|
|
gptkbp:treatment
|
radiation therapy
Surgery
Chemotherapy
Targeted therapy
|
|
gptkbp:bfsParent
|
gptkb:High-grade_glioma
|
|
gptkbp:bfsLayer
|
8
|